P2RY1 and HIV-1 infection: While a broad range of purinergic receptor antagonists have been demonstrated to inhibit HIV-1 infection [99,100,101,102,103,104,105], only P2RX1-specific compounds have been implicated in HIV-1 membrane fusion.